Neoantigen Targeted Therapies Market Key Highlights and Future Opportunities Till 2035 Neoantigen-targeted therapies aim to stimulate personalized anti-tumor immune responses by focusing on tumor-specific mutations. Approaches include personalized vaccines, cell therapies, and combination regimens with checkpoint inhibitors. Multiple candidates are advancing in clinical development, supported by strong venture funding and strategic partnerships. Driving this innovation is the Neoantigen Targeted Therapies Market, valued at USD 661 million in 2025 and projected to reach USD 807 million in 2026 and approximately USD 2.9 billion by 2030 at a CAGR of around 38%. Personalized and off-the-shelf strategies are both under evaluation across solid tumors and other indications. North America leads in clinical activity. As more late-stage data emerge and manufacturing of individualized products becomes more efficient, neoantigen approaches are expected to remain a high-growth area within immuno-oncology through the end of the decade. Read More: https://www.rootsanalysis.com/reports/neoantigen-targeted-therapies-market/257.html